Scleroderma Diagnostics and Therapeutics Market: Physician and Patient Preference to make Immunosuppressive Agents Leading Drug Category

Scleroderma, a very rare autoimmune disorder of the skin, is a term coined from the Greek words “sklerosis,” which means hardness, and “derma,” meaning skin. Thus, scleroderma literally translates to “hard skin.” Scleroderma is a group of diseases that involves the abnormal growth of connective tissue, which supports the skin and internal organs. In some forms of scleroderma, the extent of the abnormality of the disease is limited to hard, tight skin. In certain other forms, however, the predicament is worse, where the impact goes much deeper, affecting blood vessels and internal organs, such as the heart, lungs, and kidneys. Scleroderma has no known cure and is a chronic condition, in which patients are affected for life. Localized scleroderma patients, however, with mild symptoms, often see the skin patches disappear on their own in a few years post-onset.

Obtain Report Details @ http://www.transparencymarketresearch.com/scleroderma-diagnostics-therapeutics.html

This report on the global scleroderma diagnostics and therapeutics market analyzes the current and future prospects of the market. The markets of diagnostics and therapeutics are independently analyzed as two separate markets within the report. The market for scleroderma therapeutics is segmented based on drug class, indication and region, while the market for scleroderma diagnostics is segmented on the basis of test type and region. The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments. The research is a combination of primary and secondary research.

A detailed qualitative analysis of factors responsible for driving and restraining market growth and opportunities has been provided in the market overview section. Market revenue in terms of US$ Mn for the period between 2014 and 2024 along with the compound annual growth rate (CAGR %) from 2016 to 2024 are provided for all the segments, considering 2015 as the base year. Market related factors such as new drug launches, drugs in the pipeline, industry-institute collaborations in research for finding a pertinent cure, and historical year-on-year growth have been taken into consideration while estimating the market size.

Growth rates for each segment within the global scleroderma diagnostics and therapeutics market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, clinical trials, and regulatory requirements. These factors would help the market players to take strategic decisions in order to strengthen their positions and expand their share in the global market.

Based on indication, the global scleroderma diagnostics and therapeutics market has been segmented into localized and systemic scleroderma. Localized scleroderma affects only the skin, and in certain patients, the underlying muscle, however, systemic scleroderma (also known as systemic sclerosis) is much severe and affects the internal organs as well.

The major drug classes for treatment of scleroderma include Corticosteroids, Immunosuppressive Agents, Endothelin Receptor Agonists, Calcium Channel Blockers, PDE-5 Inhibitors, Chelating Agents, Prostacyclin Analogues, and Others. The others segment includes the drug classes of analgesics, proton pump inhibitors, prokinetic agents, H2 blockers and ACE inhibitors etc. which are used in symptomatic relief to the patient. Immunosuppressive agents and low dose corticosteroids are the most commonly prescribed agents to treat scleroderma.

Based on test type, the diagnostics market has been segmented into skin biopsy, imaging techniques, blood test, electrocardiogram and echocardiogram, and pulmonary function tests. Diagnosis of the disease is based on physician’s assessment of patients’ medical history and clinical manifestations. In addition, tests and procedures are undertaken to validate the clinical diagnosis and exclude alternative diagnoses, and later for assessment of organ involvement and monitoring of disease progression.

Fill the form to gain deeper insights on this market @ http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2498

Geographically, the global scleroderma diagnostics and therapeutics market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In addition, the regions have been further segmented by major countries for the scleroderma therapeutics market These include the U.S., Canada, the U.K., Germany, France, China, Japan, India, Brazil, Mexico, the UAE, and South Africa. The competition matrix section included in the report is likely to assist the existing players to increase their market shares and new companies to establish their presence in the radiodermatitis market.

The report also profiles major players in the scleroderma therapeutics and diagnostics market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include Actelion Pharmaceuticals, Inc., Boehringer Ingelheim, Bayer AG, Cytori Therapeutics, Inc., Cumberland Pharmaceuticals Inc, Gilead Sciences, Inc., Pfizer, Inc., and Sanofi.

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact Us

Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.